Textbook of clinical trials: Difference between revisions
No edit summary |
No edit summary |
||
(51 intermediate revisions by the same user not shown) | |||
Line 197: | Line 197: | ||
==Course Slides== | ==Course Slides== | ||
'''Download the slides here:'''<br> | '''Download the slides here:'''<br> | ||
===[[Media:Clinical Research Course Syllabus as of | ===[[Media:Clinical Research Course Syllabus as of 4.9.21.pdf|Clinical Research Course Syllabus]]=== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
Line 221: | Line 221: | ||
|- | |- | ||
|Lecture 6 | |Lecture 6 | ||
|[[Media: | |[[Media:(Serge Korjian).pptx|Study Design II]] | ||
|Serge Korjian | |Serge Korjian | ||
|- | |- | ||
|Lecture 7 | |Lecture 7 | ||
| | |[[Media:Phase 3 Design.pptx|Study Design Part III]] | ||
|Arzu Kalayci | |Arzu Kalayci | ||
|- | |- | ||
Line 244: | Line 244: | ||
[[Media:Intro to Observational Studies & Cohort 1.19.21.pptx|Part 2: Introduction to Observational Studies and Cohort]] | [[Media:Intro to Observational Studies & Cohort 1.19.21.pptx|Part 2: Introduction to Observational Studies and Cohort]] | ||
|Clara Fitzgerald | |Clara Fitzgerald | ||
|- | |||
|Lecture 12 | |||
|[[Media:Cross-sectional study v2.pptx|Cross-sectional studies]] | |||
|Gerald Chi | |||
|- | |||
|Lecture 13 | |||
|[[Media:ExploratoryDataAnalysis.ppt|Exploratory Data Analysis: A statistician perspective]] | |||
|Gheorghe Doros | |||
|- | |||
|Lecture 14 | |||
|[[Media:Power v2.pptx|Statistical Perspective II: power and sample size]] | |||
|Gerald Chi | |||
|- | |||
|Lecture 15 | |||
|[[Media:Association OR RR v2.pptx|Statistical Perspective III: measures of association]] | |||
|Gerald Chi | |||
|- | |||
|Lecture 16 | |||
|[[Media:CTC Regression AKK.pptx|Statistical Perspective IV: Overview of regression models]] | |||
|Arzu Kalayci | |||
|- | |||
|Lecture 17 | |||
|[[Media:PERFUSE Clinical Trial Course - Ethics Part 1 Posted.pptx|Ethics of clinical trial I]] | |||
|Clara Fitzgerald | |||
|- | |||
|Lecture 18 | |||
|[[Media:PERFUSE Clinical Trial Course - Ethics Part 2.pptx|Ethics of clinical trial II]] | |||
|Sonia Ammu | |||
|- | |||
|Lecture 19 | |||
|[[Media:PERFUSE Clinical Trial Course Running a Clinical Trial Part 1.pptx|Running a Clinical Trial part I & II]] | |||
|Maria Ok | |||
|- | |||
|Lecture 20 | |||
|[[Media:PERFUSE Clinical Trial Course GxP and Audits 09Apr2021.pptx|Running a Clinical Trial part III]] | |||
|Danielle Feingold | |||
|- | |||
|Lecture 21 | |||
|[[Media:Importance of Missing Data and Patient Retention by C Michael Gibson.pptx|Importance of missing data]] | |||
|C. Michael Gibson | |||
|- | |||
|Lecture 22 | |||
|[[Media:The Role of AROs In Clinical Research Don Cutlip April 2021.pptx|The Role of Academic Research Organizations in Clinical Research Sponsor]] | |||
|Donald E. Cutlip | |||
|- | |||
|Lecture 23 | |||
|[[Media:PERFUSE Clinical Trial Course - Clinical Events Committee (CEC).pptx|Clinical Event Committee]] | |||
|David Weiss | |||
|- | |||
|Lecture 24 | |||
|[[Media:Ciaranca, Sam DMC Overview Final 11MAY2021.pptx|Data Review Committee III, Data and Safety Monitoring Board]] | |||
|Sam Ciaranca | |||
|- | |||
|Lecture 25 | |||
|[[Media:PERFUSE Clinical Trial Course - Role of the PI.PPTX|The role of the principal investigator in clinical trials]] | |||
|Clara Fitzgerald | |||
|- | |||
|Lecture 26 | |||
|[[Media:CTC Authorship AKK.PPTX|Authorship]] | |||
|Arzu Kalayci | |||
|- | |||
|Lecture 27 | |||
|[[Media:PERFUSE Clinical Trial Course - presentation of data.pptx|Presentation of data]] | |||
|Clara Fitzgerald | |||
|- | |||
|Lecture 28 | |||
|[[Media:Interpretation.zip|Interpretation of the data]] | |||
|Gerald Chi | |||
|- | |||
|Lecture 29 | |||
|[[Media:FW Clinical Research Course Suggestions.zip|Visual abstract]] | |||
|Sadaf Sharfaei | |||
|} | |} |
Latest revision as of 19:05, 6 July 2021
Ethical Issues
Investigational Review Board (IRB)
HIPAA deidentification and reidentification of patients and patient privacy
Regulatory Issues and Pathways in Clinical Trials
The 1572 form and investigator responsibilities
Investigational new drug (IND) application
Investigational new drug or device exemption
Designing Clinical Trials
Randomized controlled trials versus observational studies
Pharmacokinetic (PK) and pharmcodynamic (PD) assessment
Advancing from phase 2 to a phase 3 trial
Parallel versus dose escalation studies
Inclusion and exclusion criteria
Secondary endpoints and exploratory endpoints
Sample size and power calculations
Abbreviations used in clinical trials
Operationalizing Clinical Trials
Nurse coordinator clinical research associate role
Recruitment of study participants
Clinical event committee or event adjudication committee (CEC)
Adverse events, serious adverse events and serious unexpected events
Data safety monitoring board (DSMB)
Storage and handling of the investigational product
Data management and designing an electronic data capture form
Study completion and close out
Statistical Analysis of Clinical Trials
Intent to treat versus modified intent to treat versus as treated
Student's t tests and analysis of variance (ANOVA)
Chi square analysis and Fisher's exact test
Subgroup and interaction analyses
Quality-adjusted life year analyses
Study Tools
Bleeding: ACUITY HORIZONS bleeding criteria ● Bleeding Academic Research Consortium ● CURE bleeding criteria ● GRACE bleeding criteria ● GUSTO bleeding criteria ● PLATO bleeding criteria ● STEEPLE bleeding criteria ● TIMI bleeding criteria
Calculators: GFR calculation ● Wells score calculation ● Caprini score calculation ● CHA2DS2-VASc score calculation ● DAPT score calculation ● TIMI risk score calculation
Differential Diagnosis: D/D of Anemia ● D/D of CK elevation ● D/D of Chest Pain
Other: Abbreviations ● Hy's law
Risk Score: GRACE risk score ● TIMI risk score
Course Slides
Download the slides here: